| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Divisions of Human Genetics and Molecular Biology [J. A. B., L. T., F. Z., L. W.] and Department of Pathology [J. A. B., P. R., L. B. R.], The Children’s Hospital of Philadelphia, and Department of Pediatrics [J. A. B.], University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Germ-line and acquired mutations of the hSNF5/INI1 tumor suppressor gene have been reported in central nervous system (CNS), renal, and soft-tissue rhabdoid tumors. The present study was designed to compare the types of INI1 alterations among tumors from diverse anatomical sites and identify mutation hot spots. Fluorescence in situ hybridization and PCR-based microsatellite, heteroduplex, and sequence analysis were used to characterize chromosome 22 deletions and INI1 mutations among 100 primary rhabdoid tumors. Deletions and/or mutations of INI1 were detected in 75 patients, including 42 children with atypical teratoid/rhabdoid tumors of the brain or spinal cord and 6 children with a brain and a renal or soft-tissue tumor. Nineteen tumors arose in the kidney (in one child, bilaterally) and eight tumors were extra-renal. Homozygous deletions detected by fluorescence in situ hybridization were most often seen in CNS and extra-renal rhabdoid tumors, whereas truncating mutations were detected in a high percentage of CNS and kidney tumors. The highest frequencies of INI1 mutations for kidney tumors were seen in exons 2, 6, and 7, compared with exons 5 and 9 for CNS tumors. Two potential hot-spot mutations for CNS atypical teratoid/rhabdoid tumors were noted, including a C-to-T transition in codon 201 in exon 5 and a cytosine deletion in exon 9. Germ-line mutations were noted in 10 children, including 4 patients with two primary tumors. The majority of rhabdoid tumors from all sites contained deletions and/or mutations of the INI1 gene. Specific mutations were nonrandomly associated with anatomical site.
This article has been cited by other articles:
|
|
 |
|
  L. Lafay-Cousin and D. Strother Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors Oncologist, April 1, 2009; 14(4): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Jackson, A. J. Sievert, X. Gai, H. Hakonarson, A. R. Judkins, L. Tooke, J. C. Perin, H. Xie, T. H. Shaikh, and J. A. Biegel Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors Clin. Cancer Res., March 15, 2009; 15(6): 1923 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J Swensen, J Keyser, C M Coffin, J A Biegel, D H Viskochil, and M S Williams Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1 J. Med. Genet., January 1, 2009; 46(1): 68 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Izawa, J. Yamate, S. Takeda, D. Kumagai, and M. Kuwamura Cutaneous Rhabdoid Tumor in a Cat Vet. Pathol., November 1, 2008; 45(6): 897 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Katsumi, Y. Kuwahara, S. Tamura, K. Kikuchi, O. Otabe, K. Tsuchiya, T. Iehara, H. Kuroda, H. Hosoi, and T. Sugimoto Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity Clin. Cancer Res., February 15, 2008; 14(4): 1192 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, X. Lun, H. Zhou, L. Wang, B. Sun, J. C. Bell, J. W. Barrett, G. McFadden, J. A. Biegel, D. L. Senger, et al. Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1218 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Zraly, F. A. Middleton, and A. K. Dingwall Hormone-response Genes Are Direct in Vivo Regulatory Targets of Brahma (SWI/SNF) Complex Function J. Biol. Chem., November 17, 2006; 281(46): 35305 - 35315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.P. Meyers, Z.P. Khademian, J.A. Biegel, S.H. Chuang, D.N. Korones, and R.A. Zimmerman Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes. AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 962 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Klochendler-Yeivin, E. Picarsky, and M. Yaniv Increased DNA Damage Sensitivity and Apoptosis in Cells Lacking the Snf5/Ini1 Subunit of the SWI/SNF Chromatin Remodeling Complex. Mol. Cell. Biol., April 1, 2006; 26(7): 2661 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Allen, A. R. Judkins, M. K. Rosenblum, and J. A. Biegel Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: Case study Neuro-oncol, January 1, 2006; 8(1): 79 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Tomlinson, N. E. Breslow, J. Dome, K. A. Guthrie, P. Norkool, S. Li, P. R.M. Thomas, E. Perlman, J. B. Beckwith, G. J. D'Angio, et al. Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor J. Clin. Oncol., October 20, 2005; 23(30): 7641 - 7645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Nagl Jr., A. Patsialou, D. S. Haines, P. B. Dallas, G. R. Beck Jr., and E. Moran The p270 (ARID1A/SMARCF1) Subunit of Mammalian SWI/SNF-Related Complexes Is Essential for Normal Cell Cycle Arrest Cancer Res., October 15, 2005; 65(20): 9236 - 9244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Modena, E. Lualdi, F. Facchinetti, L. Galli, M. R. Teixeira, S. Pilotti, and G. Sozzi SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas Cancer Res., May 15, 2005; 65(10): 4012 - 4019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Tekautz, C. E. Fuller, S. Blaney, M. Fouladi, A. Broniscer, T. E. Merchant, M. Krasin, J. Dalton, G. Hale, L. E. Kun, et al. Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy J. Clin. Oncol., March 1, 2005; 23(7): 1491 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hilden, S. Meerbaum, P. Burger, J. Finlay, A. Janss, B. W. Scheithauer, A. W. Walter, L. B. Rorke, and J. A. Biegel Central Nervous System Atypical Teratoid/Rhabdoid Tumor: Results of Therapy in Children Enrolled in a Registry J. Clin. Oncol., July 15, 2004; 22(14): 2877 - 2884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Guidi, T. M. Veal, S. N. Jones, and A. N. Imbalzano Transcriptional Compensation for Loss of an Allele of the Ini1 Tumor Suppressor J. Biol. Chem., February 6, 2004; 279(6): 4180 - 4185. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
